Walmart settles U.S. opioid lawsuit

Walmart and the U.S. Department of Justice have reached a settlement resolving a federal lawsuit that accused the retailer’s pharmacies of unlawfully dispensing opioid prescriptions. The announcement was made on August 28, 2026, with both sides confirming that the matter has been resolved. The lawsuit centered on allegations that Walmart pharmacies failed to comply with obligations under the Controlled Substances Act when dispensing opioids and other controlled substances.

In a public statement, the Justice Department said it was pleased to have reached a settlement addressing the alleged compliance failures. Walmart stated that it was pleased to resolve the matter and emphasized its intention to continue supporting the work of its pharmacists in providing patient care. The settlement brings an end to a high-profile federal case that had focused on the role of a major national pharmacy operator in the broader opioid crisis.

Multiple public statements and reports noted that the specific terms of the settlement were not disclosed. Neither the Justice Department nor Walmart provided details on any financial payments or additional obligations stemming from the agreement. As a result, the exact monetary or operational impact of the settlement remains confidential.

A joint stipulation dismissing the case was filed in federal court in Wilmington, Delaware, formally moving to end the litigation. The filing marks the procedural closure of the Justice Department’s lawsuit against Walmart over its dispensing practices. With the stipulation in place, the federal case is effectively concluded, subject to the court’s acceptance of the dismissal.

Following the settlement announcement, Walmart’s shares rose about 0.5% in morning trading. The modest share price increase suggests investors reacted to the removal of the legal uncertainty surrounding the federal opioid case. Market coverage linked the stock move to the resolution of the litigation rather than to any specific, undisclosed terms of the settlement.

Walmart has indicated that, after resolving the case, it will continue to support the work of its pharmacists in delivering patient care. The settlement closes a significant federal legal challenge to the company’s pharmacy operations under the Controlled Substances Act. While detailed conditions of the agreement have not been made public, the conclusion of the case reduces regulatory and legal overhang tied to the government’s allegations.